Aurobindo Pharma Ltd.

NSE: AUROPHARMA | BSE: 524804 | ISIN: INE406A01037 | Industry: Pharmaceuticals
| Mid-range Performer
1130.1000 -0.20 (-0.02%)
NSE Oct 13, 2025 12:18 PM
Volume: 995.7K
 

1130.10
-0.02%
ICICI Securities Limited
ICICI Securities Ltd | Retail Equity Research Revenues declined 3.5% YoY to | 3642 crore (I-direct estimate: | 3774 crore) mainly due to an 8% decline in Europe to | 777 crore (Idirect estimate: | 848 crore) and 20% decline in ARV business to | 262 crore (I-direct estimate: | 345 crore). US growth was flat YoY at | 1643 crore (I-direct estimate: | 1634 crore) EBITDA margins fell 318 bps YoY to 19.8% (I-direct estimate: 22.5%) mainly due to one-off inventory write-off and higher employee cost Adjusted net profit fell 5% YoY to | 513 crore (I-direct estimate: | 531...
Aurobindo Pharma Ltd. has an average target of 1403.50 from 10 brokers.
More from Aurobindo Pharma Ltd.
Recommended